Abstract
Objective
. To investigate the relationship between polymorphism of
TNFRSF11
gene
rs9533156
and
rs2277438
and susceptibility to gastric cancer.
Methods
. A case-control study was conducted to select 577 cases of primary gastric cancer and 678 cases of normal control. We extracted whole blood genomic DNA and amplified the target gene fragment by PCR. The genotyping and allele were tested through the snapshot method.
Results
. In this case-control study, we observed that there was a difference in the genotype distribution of
TNFRSF11
gene
rs9533156
between the case group and the control group. The frequency distribution of TC heterozygous mutation in the case group was higher than that in the control group. The smoking rate in the case group (34.49%) was higher than that in the control group (27.29%), and the difference in frequency distribution between the two groups was statistically significant (
P
=
0.006
). Our findings suggest that
TNFRSF11 rs9533156
is associated with susceptibility to GC, which is more evident among elderly patients (>62 years), nonsmokers, and patients who do not consume alcohol. The analysis of the relationship between the
TNFSF11
gene
rs9533156
site variant and clinical factors of gastric cancer showed that, compared with the tumor size <2 cm group, patients with tumor size ≥2 cm and whom carrying
rs9533156
site mutations had a higher frequency distribution, and the difference was statistically significant (
P
=
0.022
). Compared with the nonhyperglycemic group, the frequency distribution of patients with
rs9533156
site mutations in the diabetes group was higher, and the difference was statistically significant (
P
<
0.001
).
Conclusion
. This study shows that there is a correlation between smoking and the occurrence of gastric cancer. Based on our research, the functional SNP
TNFRSF11
TC genotype may be an indicator of individual susceptibility to GC. The mutation at
rs9533156
may be related to the size of gastric cancer. The mutation rate of
rs9533156
of
TNFSF11
gene is higher in diabetic gastric cancer patients.